Monday, March 23, 2020 8:00:16 AM
Recent AYTU News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/03/2026 09:08:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 09:05:35 PM
- Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results • ACCESS Newswire • 02/03/2026 09:05:00 PM
- Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 • ACCESS Newswire • 01/27/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 09:05:29 PM
- Aytu BioPharma Recaps Investor Day Held on January 20, 2026 • ACCESS Newswire • 01/20/2026 09:05:00 PM
- Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA • ACCESS Newswire • 01/20/2026 02:00:00 PM
- Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 • ACCESS Newswire • 01/13/2026 09:15:00 PM
- Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City • ACCESS Newswire • 01/12/2026 01:00:00 PM
- Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City • ACCESS Newswire • 12/18/2025 02:00:00 PM
- Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults • ACCESS Newswire • 12/15/2025 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/10/2025 09:05:23 PM
- Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference • ACCESS Newswire • 11/24/2025 09:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2025 06:26:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 09:11:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:08:28 PM
- Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results • ACCESS Newswire • 11/13/2025 09:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:35:20 PM
- Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025 • ACCESS Newswire • 11/05/2025 09:05:00 PM
- Aytu BioPharma Announces Patent Term Extension for EXXUA(TM) • ACCESS Newswire • 10/28/2025 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/24/2025 08:03:13 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/24/2025 08:02:41 PM
- Aytu BioPharma to Present at Upcoming October 2025 Conferences • ACCESS Newswire • 10/10/2025 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/07/2025 08:16:28 PM
FEATURED ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • Mar 24, 2026 8:30 AM
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
